Clinical impact of antibiotic-resistant Gram-positive pathogens

Clinical Microbiology and Infection

Volumn 15, Issue 3, 2009, Pages 212-217

  Lode, Haloheck M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Clinical impact; Drug resistant pneumococci; MRSA; Review; VRE

Indexed keywords

CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; MACROLIDE; METICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL TRANSMISSION; BLOODSTREAM INFECTION; DRUG TREATMENT FAILURE; EMPIRICISM; EUROPEAN UNION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 63249089033     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02738.x     Document Type: Review

References (49)

1. Gyssens IC. All EU hands to the EU pumps: The Science Academies of Europe (EASAC) recommend strong support of research to tackle antibacterial resistance. Clin Microbiol Infect 2008; 14: 889-891.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: No ESKAPE!An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006; 42: S65-S71.
4. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46: S360-S367.
5. Sievert DM, Rudrik JT, Patel JB et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46: 668-674.
6. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42: S82-S89.
7. Kaye KS, Engemann JJ, Mozaffari E et al. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004; 10: 1125-1128.
8. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
9. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
10. File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: A new perspective. Clin Infect Dis 2006; 42: 798-800.
11. Pallares R, Liñares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
12. Metlay JP. Antibacterial drug resistance: Implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 777-790.
13. Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33: 797-805.
14. Yu VL, Chiou CC, Feldman C et al. for the International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237.
15. Tleyjeh IM, Tlaygeh HM, Hejal R et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: A systematic review and meta-analysis. Clin Infect Dis 2006; 42: 788-797.
16. Aspa J, Rajas O, Rodríguez de Castro F et al. Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors. Clin Infect Dis 2004; 38: 787-798.
17. Lode HM. Managing community-acquired pneumonia: A European perspective. Respir Med 2007; 101: 1864-1873.
18. Henriques B, Kalin M, Ortqvist A et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000; 182: 833-839.
19. Musher DM, Dowell ME, Shortridge VD et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630-631.
20. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-1011.
21. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-564.
22. Van Kerkhoven D, Peetermans WE, Verbist L et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51: 691-696.
23. Daneman N, McGeer A, Green K et al. Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43: 432-438.
24. Mandell LA, Wunderink RG, Anzueto A et al. American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-S72.
25. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: Does in vitro resistance really matter? Clin Infect Dis 2006; 42: 224-233.
26. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; 1: 904-907.
27. Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368: 874-885.
28. Liu C, Graber CJ, Karr M et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis 2008; 46: 1637-1646.
29. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-59.
30. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-174.
31. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26: 175-183.
32. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 1: 36.
33. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: Risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008; 198: 336-343.
34. Uttley AH, Collins CH, Naidoo J et al. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-58.
35. Edmond MB, Ober JF, Dawson JD et al. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234-1239.
36. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145-158.
37. Carmeli Y, Eliopoulos G, Mozaffari E et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-2228.
38. DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis. Clin Infect Dis 2005; 41: 327-333.
39. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191: 588-595.
40. Garbutt JM, Ventrapragada M, Littenberg B. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30: 466-472.
41. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323.
42. Linden PK, Pasculle AW, Manez R et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: 663-670.
43. Lodise TP, McKinnon PS, Tam VH et al. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34: 922-929.
44. Lucas GM, Lechtzin N, Puryear DW. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127-1133.
45. Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993-1000.
46. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135: 484-492.
47. Chou YY, Lin TY, Lin JC et al. Vancomycin-resistant enterococcal bacteremia: Comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect 2008; 41: 124-129.
48. Wright GD, Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol Med 2007; 13: 260-267.
49. European Academies Science Advisory Council. Tackling antibacterial resistance in Europe. AESAC policy report. London: The Royal Society, 2007. Available at: http://www.easac.eu/document.asp?id=31 (last accessed 19 August 2008).